80 related articles for article (PubMed ID: 23306922)
1. [Effectiveness of steroids for the rash side effect of pemetrexed].
Ishikawa H; Onishi T; Kobayashi R; Ohashi Y; Suzuki K; Yamamoto N; Shino M
Gan To Kagaku Ryoho; 2013 Jan; 40(1):75-8. PubMed ID: 23306922
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids.
Sakurada T; Kakiuchi S; Tajima S; Horinouchi Y; Konaka K; Okada N; Nishisako H; Nakamura T; Teraoka K; Kawazoe K; Yanagawa H; Nishioka Y; Ishizawa K
Biol Pharm Bull; 2015; 38(11):1752-6. PubMed ID: 26521826
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed-associated urticarial vasculitis.
Lopes G; Vincek V; Raez LE
Lung Cancer; 2006 Feb; 51(2):247-9. PubMed ID: 16360237
[TBL] [Abstract][Full Text] [Related]
4. [Management and maintenance of pemetrexed monotherapy regimen - initial experience of pretreated non-small cell lung cancer].
Takase M; Maruoka H; Ametani F; Takahashi M; Shibata K
Gan To Kagaku Ryoho; 2012 Apr; 39(4):563-5. PubMed ID: 22504678
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours.
Nakagawa K; Kudoh S; Matsui K; Negoro S; Yamamoto N; Latz JE; Adachi S; Fukuoka M
Br J Cancer; 2006 Sep; 95(6):677-82. PubMed ID: 16940981
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
Kuribayashi K; Voss S; Nishiuma S; Arakawa K; Nogi Y; Mikami K; Kudoh S
Lung Cancer; 2012 Mar; 75(3):353-9. PubMed ID: 21890228
[TBL] [Abstract][Full Text] [Related]
8. Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction.
Bracke A; Van Marck E; Lambert J
Clin Exp Dermatol; 2009 Apr; 34(3):337-9. PubMed ID: 18699838
[TBL] [Abstract][Full Text] [Related]
9. [Safety of pemetrexed mono-therapy in elderly patients with non-small cell lung cancer].
Konishi A; Kitada N; Nanjo S; Tanaka S; Tomii K; Katakami N; Hashida T
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1507-10. PubMed ID: 23064061
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
11. Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study.
Sakurada T; Nokihara H; Koga T; Zamami Y; Goda M; Yagi K; Hamano H; Aizawa F; Ogino H; Sato S; Kirino Y; Goto H; Nishioka Y; Ishizawa K
Oncologist; 2022 Jul; 27(7):e554-e560. PubMed ID: 35325241
[TBL] [Abstract][Full Text] [Related]
12. Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash.
Usui N; Kondo Y; Ryota N; Suzuki H; Okamoto N; Sando M; Tani E; Hamaguchi M; Tanaka A; Tamiya M; Shiroyama T; Morishita N; Tanaka E; Hirashima T
Eur J Hosp Pharm; 2017 Sep; 24(5):283-285. PubMed ID: 29308196
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss.
Battaglia A; Burchette R; Cueva R
Otol Neurotol; 2008 Jun; 29(4):453-60. PubMed ID: 18401285
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed-induced eyelid edema: incidence and clinical manifestations.
Schallier D; Decoster L; Fontaine C; De Grève J
Anticancer Res; 2010 Dec; 30(12):5185-8. PubMed ID: 21187510
[TBL] [Abstract][Full Text] [Related]
17. [Adverse events during pemetrexed administration caused by concomitant nonsteroid anti-inflammatory therapy].
Sakata Y; Iwamoto Y; Inata J; Matsumoto S; Miyamori S; Nakashima K; Sakamoto S; Kanehara M; Kitaguchi S; Hiraki K
Gan To Kagaku Ryoho; 2012 Jun; 39(6):927-32. PubMed ID: 22705687
[TBL] [Abstract][Full Text] [Related]
18. FDA drug approval summaries: pemetrexed (Alimta).
Hazarika M; White RM; Johnson JR; Pazdur R
Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
[TBL] [Abstract][Full Text] [Related]
19. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.
Haynes DS; O'Malley M; Cohen S; Watford K; Labadie RF
Laryngoscope; 2007 Jan; 117(1):3-15. PubMed ID: 17202923
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed-induced edema of the eyelid.
Kurata T; Tamura K; Okamoto I; Satoh T; Nakagawa K; Fukuoka M
Lung Cancer; 2006 Nov; 54(2):241-2. PubMed ID: 16996165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
